ADRB2 and prostate carcinoma: Actually, ADRB2 was the strongest predictor of clinical failure in the study by Yu et al. Validation studies also addressing a potential association with metastasis, development of castration resistance, and survival is warranted to determine whether ADRB2 is a clinically relevant prognostic marker in prostate cancer.